149 related articles for article (PubMed ID: 36870097)
1. Clinical outcomes of pelvic exenteration for gynecologic malignancies.
Moolenaar LR; van Rangelrooij LE; van Poelgeest MIE; van Beurden M; van Driel WJ; van Lonkhuijzen LRCW; Mom CH; Zaal A
Gynecol Oncol; 2023 Apr; 171():114-120. PubMed ID: 36870097
[TBL] [Abstract][Full Text] [Related]
2. Pelvic exenteration for gynecologic malignancies: The experience of a tertiary center from Greece.
Haidopoulos D; Pergialiotis V; Aggelou K; Thomakos N; Alexakis N; Stamatakis E; Rodolakis A
Surg Oncol; 2022 Mar; 40():101702. PubMed ID: 35065392
[TBL] [Abstract][Full Text] [Related]
3. Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort.
Straubhar AM; Chi AJ; Zhou QC; Iasonos A; Filippova OT; Leitao MM; Awowole IO; Abu-Rustum NR; Broach VA; Jewell EL; Sandhu JS; Sonoda Y
Gynecol Oncol; 2021 Nov; 163(2):294-298. PubMed ID: 34518053
[TBL] [Abstract][Full Text] [Related]
4. Pelvic Exenteration in Advanced Gynecologic Malignancies - Who Will Benefit?
Egger EK; Liesenfeld H; Stope MB; Recker F; Döser A; Könsgen D; Marinova M; Hilbert T; Exner D; Ellinger J; Mustea A
Anticancer Res; 2021 Jun; 41(6):3037-3043. PubMed ID: 34083295
[TBL] [Abstract][Full Text] [Related]
5. A modern-day experience with Brunschwig's operation: Outcomes associated with pelvic exenteration.
Rios-Doria E; Filippova OT; Straubhar AM; Chi A; Awowole I; Sandhu J; Broach V; Mueller JJ; Gardner GJ; Jewell EL; Zivanovic O; Leitao MM; Long Roche K; Abu-Rustum NR; Sonoda Y
Gynecol Oncol; 2022 Nov; 167(2):277-282. PubMed ID: 36064678
[TBL] [Abstract][Full Text] [Related]
6. Overall survival after pelvic exenteration for gynecologic malignancy.
Westin SN; Rallapalli V; Fellman B; Urbauer DL; Pal N; Frumovitz MM; Ramondetta LM; Bodurka DC; Ramirez PT; Soliman PT
Gynecol Oncol; 2014 Sep; 134(3):546-51. PubMed ID: 25014540
[TBL] [Abstract][Full Text] [Related]
7. Total pelvic exenteration for primary and recurrent malignancies.
Ferenschild FT; Vermaas M; Verhoef C; Ansink AC; Kirkels WJ; Eggermont AM; de Wilt JH
World J Surg; 2009 Jul; 33(7):1502-8. PubMed ID: 19421811
[TBL] [Abstract][Full Text] [Related]
8. Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases.
de Gregorio N; de Gregorio A; Ebner F; Friedl TWP; Huober J; Hefty R; Wittau M; Janni W; Widschwendter P
Arch Gynecol Obstet; 2019 Jul; 300(1):161-168. PubMed ID: 31011878
[TBL] [Abstract][Full Text] [Related]
9. The impact of distance to closest negative margin on survival after pelvic exenteration.
Martin AL; Sinha S; Peres LC; Hakam A; Chon HS; Hoffman MS; Shahzad MM; Wenham RM; Chern JY
Gynecol Oncol; 2022 Jun; 165(3):514-521. PubMed ID: 35487774
[TBL] [Abstract][Full Text] [Related]
10. [Outcomes of perisurgery and short-time follow-up of pelvic exenteration for 17 cases with locally recurrent cervical cancer].
Deng H; Wang JL; Wang ZQ; Li XW; Hu H; Yang B; Zhang XM; Shen K; Guo P; Liang B
Zhonghua Fu Chan Ke Za Zhi; 2020 Apr; 55(4):259-265. PubMed ID: 32375433
[No Abstract] [Full Text] [Related]
11. Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies.
Fotopoulou C; Neumann U; Kraetschell R; Schefold JC; Weidemann H; Lichtenegger W; Sehouli J
J Surg Oncol; 2010 May; 101(6):507-12. PubMed ID: 20401918
[TBL] [Abstract][Full Text] [Related]
12. Indications for primary and secondary exenterations in patients with cervical cancer.
Marnitz S; Köhler C; Müller M; Behrens K; Hasenbein K; Schneider A
Gynecol Oncol; 2006 Dec; 103(3):1023-30. PubMed ID: 16890276
[TBL] [Abstract][Full Text] [Related]
13. Influence of tumor size on outcomes following pelvic exenteration.
Smith B; Jones EL; Kitano M; Gleisner AL; Lyell NJ; Cheng G; McCarter MD; Abdel-Misih S; Backes FJ
Gynecol Oncol; 2017 Nov; 147(2):345-350. PubMed ID: 28822555
[TBL] [Abstract][Full Text] [Related]
14. Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery.
Andikyan V; Khoury-Collado F; Sonoda Y; Gerst SR; Alektiar KM; Sandhu JS; Bochner BH; Barakat RR; Boland PJ; Chi DS
Gynecol Oncol; 2012 May; 125(2):404-8. PubMed ID: 22285844
[TBL] [Abstract][Full Text] [Related]
15. Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution.
Jäger L; Nilsson PJ; Rådestad AF
Int J Gynecol Cancer; 2013 May; 23(4):755-62. PubMed ID: 23407096
[TBL] [Abstract][Full Text] [Related]
16. Pelvic exenteration with curative intent for recurrent uterine malignancies.
Khoury-Collado F; Einstein MH; Bochner BH; Alektiar KM; Sonoda Y; Abu-Rustum NR; Brown CL; Gardner GJ; Barakat RR; Chi DS
Gynecol Oncol; 2012 Jan; 124(1):42-7. PubMed ID: 22014627
[TBL] [Abstract][Full Text] [Related]
17. Complications and survival after total pelvic exenteration.
Pleth Nielsen CK; Sørensen MM; Christensen HK; Funder JA
Eur J Surg Oncol; 2022 Jun; 48(6):1362-1367. PubMed ID: 34998633
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of pelvic exenterations for gynecological malignancies: a single-center retrospective cohort study.
Yu JH; Tong CJ; Huang QD; Ye YL; Chen G; Li H; Wen YS; Yang F; Luo NB; Xu GY; Xiong Y
BMC Cancer; 2024 Jan; 24(1):88. PubMed ID: 38229045
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in pelvic exenteration for gynecological malignancies.
Baiocchi G; Guimaraes GC; Rosa Oliveira RA; Kumagai LY; Faloppa CC; Aguiar S; Begnami MD; Soares FA; Lopes A
Eur J Surg Oncol; 2012 Oct; 38(10):948-54. PubMed ID: 22818842
[TBL] [Abstract][Full Text] [Related]
20. The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration.
Burger IA; Vargas HA; Donati OF; Andikyan V; Sala E; Gonen M; Goldman DA; Chi DS; Schöder H; Hricak H
Gynecol Oncol; 2013 Jun; 129(3):586-592. PubMed ID: 23369941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
